A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors

The objective of this study was to determine the prognostic value of lymph node (LN) involvement and the LN ratio (LNR) and their effect on recurrence rates and survival in patients with pancreatic neuroendocrine tumors (PNETs) undergoing surgery. This single-center retrospective study reviewed the medical records of 95 consecutive patients diagnosed with PNETs who underwent surgery at our medical center between 1997 and 2017. The retrieved information included patient demographics, pathology reports, treatments, and oncological outcomes. Results: 95 consecutive potentially suitable patients were identified. The 78 patients with PNETs who underwent surgery and for whom there was adequate data were included in the analysis. Their mean ± standard deviation age at diagnosis was 57.4 ± 13.4 years (range 20–82), and there were 50 males (64%) and 28 females (36%). 23 patients (30%) had LN metastases (N1). The 2.5- and 5-year disease-free survival (DFS) rates for the entire cohort were 79.5% and 71.8%, respectively, and their 2- and 5-year overall survival (OS) rates were 85.9% and 82.1%, respectively. The optimal value of the LNR was 0.1603, which correlated with the outcome (2-year OS p = 0.002 HR = 13.4 and 5-year DFS p = 0.016 HR = 7.2, respectively, and 5-year OS and 5-year DFS p = 0.004 HR = 9 and p = 0.001 HR = 10.6, respectively). However, the multivariate analysis failed to show that the LNR was an independent prognostic factor in PNETs. Patients with PNETs grade and stage are known key prognostic factors influencing OS and DFS. According to our results, LNR failed to be an independent prognostic factor.

[1]  M. Picchio,et al.  A Single-center Prospective Observational Study Investigating the Accuracy of Preoperative Diagnostic Procedures in the Assessment of Lymph Node Metastases in Nonfunctioning Pancreatic Neuroendocrine Tumors , 2022, Annals of surgery.

[2]  M. Falconi,et al.  RELIABILITY OF PREOPERATIVE PANCREATIC NEUROENDOCRINE TUMORS GRADING ON ENDOSCOPIC ULTRASOUND SPECIMENS: A SYSTEMATIC REVIEW WITH META-ANALYSIS OF AGGREGATE AND INDIVIDUAL DATA. , 2022, Gastrointestinal endoscopy.

[3]  Yijun Wang,et al.  Prognostic Nomogram Based on the Metastatic Lymph Node Ratio for T1-4N0-1M0 Pancreatic Neuroendocrine Tumors After Surgery , 2022, Frontiers in Oncology.

[4]  Wenquan Wang,et al.  Patterns and predictors of pancreatic neuroendocrine tumor prognosis: Are no two leaves alike? , 2021, Critical reviews in oncology/hematology.

[5]  C. Bassi,et al.  Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases , 2021, Neuroendocrinology.

[6]  F. Giovinazzo,et al.  mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs) , 2020, Frontiers in Endocrinology.

[7]  K. Lillemoe,et al.  Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma , 2020, Annals of surgery.

[8]  R. Bundschuh,et al.  Therapy of Patients with Neuroendocrine Neoplasia—Evidence-Based Approaches and New Horizons , 2019, Journal of clinical medicine.

[9]  elliot k fishman,et al.  Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Berlin,et al.  Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.

[11]  C. Schade-Brittinger,et al.  Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival , 2016, Neuroendocrinology.

[12]  R. Jensen,et al.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors , 2016, Neuroendocrinology.

[13]  Xiaxing Deng,et al.  Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors , 2015, Chinese medical journal.

[14]  P. Ruszniewski,et al.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors. , 2014, The New England journal of medicine.

[15]  K. Trinkaus,et al.  Regional Lymphadenectomy Is Indicated in the Surgical Treatment of Pancreatic Neuroendocrine Tumors (PNETs) , 2014, Annals of surgery.

[16]  P. Balladur,et al.  Number of examined lymph nodes and nodal status assessment in pancreaticoduodenectomy for pancreatic adenocarcinoma. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  A. Scarpa,et al.  Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. , 2012, European journal of cancer.

[18]  A. Benson,et al.  The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. , 2011, International journal of radiation oncology, biology, physics.

[19]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[20]  H. Ohge,et al.  Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. , 2010, Journal of the American College of Surgeons.

[21]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Scarpa,et al.  Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  C. Ko,et al.  Prognostic Score Predicting Survival After Resection of Pancreatic Neuroendocrine Tumors: Analysis of 3851 Patients , 2008, Annals of surgery.

[24]  H. Reber,et al.  Resection of pancreatic neuroendocrine tumors: results of 70 cases. , 2006, Archives of surgery.

[25]  D. Santini,et al.  Endocrine pancreatic tumors: factors correlated with survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  E. Kebebew,et al.  A Lymph Node Ratio–Based Staging Model Is Superior to the Current Staging System for Pancreatic Neuroendocrine Tumors , 2018, The Journal of clinical endocrinology and metabolism.

[27]  B. Pockaj,et al.  Importance of Lymph Node Involvement in Pancreatic Neuroendocrine Tumors: Impact on Survival and Implications for Surgical Resection , 2014, Journal of Gastrointestinal Surgery.

[28]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.